Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant

NCT04312789 is registered in ClinicalTrials.gov with Ayman Saad as lead sponsor.

NCT NCT04312789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04312789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
Ayman Saad
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2022
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platelet disorder